JP2021519087A5 - - Google Patents

Info

Publication number
JP2021519087A5
JP2021519087A5 JP2020551874A JP2020551874A JP2021519087A5 JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5 JP 2020551874 A JP2020551874 A JP 2020551874A JP 2020551874 A JP2020551874 A JP 2020551874A JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5
Authority
JP
Japan
Prior art keywords
cells
population
hdaci
teff
eff
Prior art date
Application number
JP2020551874A
Other languages
English (en)
Japanese (ja)
Other versions
JP7447011B2 (ja
JPWO2019191501A5 (https=
JP2021519087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024693 external-priority patent/WO2019191501A1/en
Publication of JP2021519087A publication Critical patent/JP2021519087A/ja
Publication of JPWO2019191501A5 publication Critical patent/JPWO2019191501A5/ja
Publication of JP2021519087A5 publication Critical patent/JP2021519087A5/ja
Priority to JP2023210666A priority Critical patent/JP2024037880A/ja
Application granted granted Critical
Publication of JP7447011B2 publication Critical patent/JP7447011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551874A 2018-03-28 2019-03-28 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用 Active JP7447011B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023210666A JP2024037880A (ja) 2018-03-28 2023-12-14 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649265P 2018-03-28 2018-03-28
US62/649,265 2018-03-28
PCT/US2019/024693 WO2019191501A1 (en) 2018-03-28 2019-03-28 Use of histone modifiers to reprogram effector t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023210666A Division JP2024037880A (ja) 2018-03-28 2023-12-14 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用

Publications (4)

Publication Number Publication Date
JP2021519087A JP2021519087A (ja) 2021-08-10
JPWO2019191501A5 JPWO2019191501A5 (https=) 2022-04-04
JP2021519087A5 true JP2021519087A5 (https=) 2022-04-04
JP7447011B2 JP7447011B2 (ja) 2024-03-11

Family

ID=68060769

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551874A Active JP7447011B2 (ja) 2018-03-28 2019-03-28 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用
JP2023210666A Pending JP2024037880A (ja) 2018-03-28 2023-12-14 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023210666A Pending JP2024037880A (ja) 2018-03-28 2023-12-14 エフェクターt細胞をリプログラムするためのヒストン修飾因子の使用

Country Status (8)

Country Link
US (2) US12173317B2 (https=)
EP (2) EP4722350A2 (https=)
JP (2) JP7447011B2 (https=)
KR (1) KR20200138325A (https=)
CN (1) CN112105368A (https=)
AU (1) AU2019243578B2 (https=)
CA (1) CA3094375A1 (https=)
WO (1) WO2019191501A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
KR20200138325A (ko) * 2018-03-28 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이펙터 t 세포를 재프로그래밍하기 위한 히스톤 개질제의 용도
KR102069704B1 (ko) * 2018-05-16 2020-01-23 고려대학교 산학협력단 Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
JP7785699B2 (ja) * 2020-05-29 2025-12-15 シャンハイ ジュンセル セラピューティクス カンパニー リミテッド 腫瘍浸潤リンパ球の種細胞培地及びその使用
GB202008957D0 (en) * 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药(香港)有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
WO2023201097A1 (en) * 2022-04-15 2023-10-19 Turn Biotechnologies, Inc. Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells
US20230355678A1 (en) * 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2006065495A2 (en) 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
RU2763795C2 (ru) * 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
KR20190033066A (ko) * 2016-06-24 2019-03-28 맥마스터 유니버시티 입양 세포 전달 및 종양붕괴 바이러스 병용 치료
KR102849343B1 (ko) 2018-03-07 2025-08-25 포세이다 테라퓨틱스, 인크. Cartyrin 조성물 및 사용 방법
KR20200138325A (ko) * 2018-03-28 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이펙터 t 세포를 재프로그래밍하기 위한 히스톤 개질제의 용도
EP3847197A1 (en) * 2018-09-05 2021-07-14 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2021519087A5 (https=)
Selck et al. Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation
Schneidawind et al. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation
Patel et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer
Gattinoni et al. T memory stem cells in health and disease
Safinia et al. Regulatory T cells: serious contenders in the promise for immunological tolerance in transplantation
US8685728B2 (en) Kit containing stem cells and cytokines for use in attenuating immune responses
Kim et al. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease
Nardo‐Marino et al. Emerging therapies in sickle cell disease
FI3578201T3 (fi) Menetelmiä ja koostumuksia luonnollisille tappajasoluille
BR112013003366A2 (pt) terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras
JPWO2019191501A5 (https=)
JP2019520823A5 (https=)
Bulliard et al. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases
Hu et al. Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation
Xu et al. Immunomodulatory effects of histone deacetylation inhibitors in graft-vs.-host disease after allogeneic stem cell transplantation
Osumi et al. Prospective study of allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and antithymocyte globulin from HLA-mismatched related donors for nonmalignant diseases
Thiolat et al. Treg-targeted IL-2/anti-IL-2 complex controls graft-versus-host disease and supports anti-tumor effect in allogeneic hematopoietic stem cell transplantation
Gagliani et al. Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation
RU2016102172A (ru) Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
JP2022023136A5 (https=)
Pierini et al. Regulatory T cell immunotherapy in immune-mediated diseases
JPWO2020081987A5 (https=)
Ott et al. Innate immune cellular therapeutics in transplantation
Composto et al. Peritoneal T lymphocyte regulation by macrophages